Authors: T.J. Sharpe
At the American Association for Cancer Research Annual Meeting 2018 (April 14–18, IL, USA),back-to-back presentations highlighted the advances in immunotherapy treatments for lung cancer, the deadliest cancer worldwide with approximately 1.7 million deaths per year . Researchers from across the globe presented their published anti-PD-1/anti-PD-L1 trials and the results will change the way some lung cancers are approached.
- Pembrolizumab (Keytruda ®) plus chemotherapy fared significantly better than chemotherapy alone in nonsquamous Non-Small Cell Lung Cancer (NSCLC) in the Keynote-189 trial, as published in The New England Journal of Medicine
- Nivolumab (Opdivo ®) plus ipilimumab (Yervoy ®) had significantly higher progression-free survival than NSCLC patients treated with chemotherapy when they had a high Tumor Mutational Burden (TMB > 10 mutations/Mb) in the CheckMate-227 trial, also published in The New England Journal of Medicine
- Atezolizumab (Tecentriq®) plus bevacizumab (Avastin®) and chemotherapy showed an improvement in progression-free survival over bevacizumab and chemotherapy in the IMpower150 trial of nonsquamous NSCLC patients